Of the 87 NSCLC cases, 74 had PSMA expression in tumor NECs, with a positive rate of 85.06% (74/87); 47 displayed PSMA expression in the tumor cells, with a positive rate of 54.02% (47/87); 40 cases had both PSMA-positive tumor cells and tumor NECs (45.98%, 40/87). The gene discussed is FOLH1; the disease is non-small cell lung carcinoma.